As the Founder and CEO of Base Pair Biotechnologies, Inc., Bill Jackson, Ph.D., has established himself as a pioneering force in the field of aptamer-based diagnostics and therapeutics. With over 12 years of experience in this specialized area, Dr. Jackson has been instrumental in driving...
As the Founder and CEO of Base Pair Biotechnologies, Inc., Bill Jackson, Ph.D., has established himself as a pioneering force in the field of aptamer-based diagnostics and therapeutics. With over 12 years of experience in this specialized area, Dr. Jackson has been instrumental in driving the company's vision to harness the unique properties of aptamers for innovative healthcare solutions. His leadership has not only focused on the development and commercialization of cutting-edge products but also on fostering a culture of scientific excellence and collaboration within the organization.
Under Dr. Jackson's guidance, Base Pair Biotechnologies has successfully secured significant non-dilutive funding through government grants and contracts, complementing private capital investments. This strategic approach has enabled the company to advance its research initiatives and bring early-stage products to market, including novel biosensors and microarray technologies that leverage the specificity and versatility of aptamers. His expertise in bioinformatics and proteomics has been crucial in optimizing these products for various applications, from diagnostics to therapeutic interventions.
Dr. Jackson's contributions to the aptamer field are underscored by his extensive publication record, which includes over 20 peer-reviewed articles and numerous conference presentations. His co-authorship of the first-ever market research report on aptamers in 2010 highlights his commitment to advancing industry knowledge and fostering innovation. As a recognized leader in the start-up ecosystem, Dr. Jackson continues to mentor emerging entrepreneurs, sharing his insights on grant writing, entrepreneurship, and the intricacies of navigating the biotechnology landscape. His vision for Base Pair Biotechnologies remains focused on transforming the future of medicine through the power of aptamer technology.
